<DOC>
	<DOCNO>NCT02145689</DOCNO>
	<brief_summary>This long-term safety efficacy study onabotulinumtoxinA poststroke patient upper limb spasticity .</brief_summary>
	<brief_title>Long-Term Study OnabotulinumtoxinA Treatment Adult Patients With Upper Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>For patient enter 191622127 study , successful completion study 191622127 For patient enter directly study 191622129 , upper limb spasticity elbow shoulder due stroke , recent stroke least 3 month ago Spasticity nonstudy upper limb require treatment Presence fix contracture study muscle elbow shoulder Profound atrophy muscle inject Previous surgical intervention , nerve block , muscle block treatment spasticity study limb last 12 month Injection corticosteroid anesthetic , use cast dynamic splinting constraintinduced movement therapy ( CIMT ) study limb within 3 month Ultrasound therapy , electrical stimulation , acupuncture study limb within 1 month Condition stroke contribute upper limb spasticity Diagnosis myasthenia gravis , EatonLambert syndrome , and/or amyotrophic lateral sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>